Intech Investment Management LLC Purchases 29,167 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Intech Investment Management LLC increased its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 224.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 42,156 shares of the company's stock after buying an additional 29,167 shares during the quarter. Intech Investment Management LLC owned 0.09% of Amphastar Pharmaceuticals worth $1,565,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC grew its holdings in shares of Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock worth $26,000 after purchasing an additional 493 shares in the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of Amphastar Pharmaceuticals by 806.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock worth $36,000 after acquiring an additional 871 shares during the period. Point72 Asia Singapore Pte. Ltd. boosted its position in shares of Amphastar Pharmaceuticals by 53.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock valued at $56,000 after acquiring an additional 398 shares in the last quarter. KBC Group NV increased its stake in Amphastar Pharmaceuticals by 43.1% in the fourth quarter. KBC Group NV now owns 2,159 shares of the company's stock valued at $80,000 after acquiring an additional 650 shares during the period. Finally, PNC Financial Services Group Inc. increased its stake in Amphastar Pharmaceuticals by 90.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,203 shares of the company's stock valued at $156,000 after acquiring an additional 1,992 shares during the period. 65.09% of the stock is currently owned by institutional investors.

Remove Ads

Amphastar Pharmaceuticals Price Performance

NASDAQ:AMPH traded down $0.07 on Tuesday, reaching $28.39. The stock had a trading volume of 713,226 shares, compared to its average volume of 427,720. The company has a market capitalization of $1.35 billion, a P/E ratio of 9.46, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77. The stock has a fifty day moving average price of $31.52 and a 200-day moving average price of $40.24. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 1-year low of $25.89 and a 1-year high of $53.96.

Wall Street Analyst Weigh In

Separately, Piper Sandler decreased their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a report on Friday.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the sale, the chief financial officer now owns 97,363 shares of the company's stock, valued at $2,681,377.02. This represents a 4.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 27.10% of the stock is owned by corporate insiders.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.